Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature.
Systemic mastocytosis (SM) are defined by an abnormal growth and accumulation of mast cells in bone marrow and/or other extracutaneous organs. There is currently no cure for this disease. Because of similarities and/or association of mastocytosis with myeloproliferative disorders, interferon alpha has been tested but with contradictory reported results. A first prospective multicenter phase II trial was then started in France. From 1994 to 1997, 20 adult patients with confirmed bone marrow involvement received interferon alpha-2b for at least 6 months, (from 1 million U per day up to 5 million U/m(2)/day). Thirteen patients who presented systemic and/or specific cutaneous manifestations, demonstrated objective responses: seven (35%) were partial, six (30%) minor but no complete response could be observed at the time of analysis. The bone marrow remained unchanged in 12/13. Thus, interferon should be offered to patients with severe systemic manifestations, who have not responded to symptomatic therapies, even in case of non-aggressive mastocytosis, with or without corticosteroids the first weeks. Long-term therapy should be offered to patients with initial positive response. To control more aggressive SM or mastocytosis associated with clonal hematologic non-mast cell lineage or leukaemia mast cell, other chemotherapeutic regimens should be proposed like Cladribine (2-chlorodeoxyadenosine, 2-CDA) or polychemotherapies including interferon as it is being tested in France in a new multicentric protocol, coordinated by the association AFIRMM, with interferon and oral cytarabine.
Simon
J
J
Service de médecine Interne-néphrologie, Centre hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, 10, rue Champ Gaillard, 78300 Poissy, France. jsimon@chi-poissy-st-germain.fr
Lortholary
O
O
Caillat-Vigneron
N
N
Raphaël
M
M
Martin
A
A
Brière
J
J
Barète
S
S
Hermine
O
O
Casassus
Ph
P
D001854:Bone Marrow Cells / Q000473:pathology; D005602:France; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008407:Mast Cells / Q000473:pathology; D034721:Mastocytosis, Systemic / Q000188:drug therapy* / Q000473:pathology
D016898:Interferon-alpha